{
  "study_id": "NCT06041152",
  "agent": "framework",
  "run": 5,
  "p_primary_hypothesis_supported": 0.12,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": -6, "high": 12, "metric": "Percent difference in SynVesT-1 volume of distribution, psilocybin vs placebo (positive = higher density after psilocybin)"},
  "moderator_prediction": "Healthy participants may show a slightly cleaner increase; aMCI tissue with ongoing synaptic loss is slower to rewrite, but with n=6 vs 4 split across drug/placebo no moderator difference will be detectable.",
  "claim_ids_used": ["PM-0058", "PM-0062", "PM-0092", "PM-0401", "PM-0028", "PM-0372"],
  "rationale": "The framework equates belief balance with synaptic connection strength (PM-0058) and says psychedelics relax high-level priors (PM-0401, PM-0028), with one saturated session booking heavily (PM-0092), so it leans toward a positive direction. But the outcome is a level-4 biomarker, beyond the render layer where effects are largest (PM-0372), and tissue changes slowly (PM-0062). Animal work shows psilocybin spinogenesis and prior SV2A PET in pigs hinted at small increases, yet one-week post-dose human effects are likely a few percent. With N=10 split into four arms (about 5 vs 5 on the drug contrast) and PET test-retest variability of ~5-10%, a significant difference is improbable."
}